Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 9
1946 37
1947 43
1948 48
1949 31
1951 8
1952 24
1953 12
1954 26
1955 20
1956 30
1957 29
1958 17
1959 55
1960 70
1961 90
1962 47
1963 2
1964 9
1965 134
1966 257
1967 332
1968 369
1969 435
1970 446
1971 574
1972 658
1973 735
1974 818
1975 850
1976 849
1977 815
1978 625
1979 683
1980 694
1981 555
1982 626
1983 598
1984 678
1985 647
1986 677
1987 597
1988 671
1989 624
1990 684
1991 733
1992 741
1993 801
1994 832
1995 881
1996 815
1997 927
1998 904
1999 933
2000 960
2001 977
2002 954
2003 925
2004 913
2005 999
2006 1067
2007 1074
2008 1034
2009 1064
2010 1054
2011 1184
2012 1313
2013 1404
2014 1402
2015 1378
2016 1345
2017 1441
2018 1398
2019 1354
2020 1374
2021 1237
2022 1023
2023 782
2024 1072
2025 1229
2026 628

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50,718 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
Shi GM, Huang XY, Liang F, Liang X, Dong R, Ye QH, Gao Q, Ji Y, Yu ZP, Zhai WL, Lu JC, Li XW, Liu FB, Wang K, Yang W, Zhang JL, Hu ZQ, Qiu SJ, Wang XY, Yang XR, Sun HC, Shi YH, Ding ZB, Liu WR, Huang XW, Huang C, Shen YH, Sun J, He YF, Peng YF, Xu Y, Zou JJ, Zhou J, Fan J; ZSAB Study Group. Shi GM, et al. N Engl J Med. 2026 Mar 5;394(10):983-995. doi: 10.1056/NEJMoa2513918. N Engl J Med. 2026. PMID: 41780001 Clinical Trial.
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.
Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D. Makker V, et al. J Immunother Cancer. 2026 Feb 19;14(2):e013713. doi: 10.1136/jitc-2025-013713. J Immunother Cancer. 2026. PMID: 41714113 Free PMC article. Clinical Trial.
Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.
Zhang X, Cai H, Peng W, Wang H, Wu J, Zhu X, Guo W, Xie F, Zhang Y, Wang M, Yu Y, Zhou Y, Li C, Shen J, Liu C, Yang Y, Jiang X, Li Q, Chen W, Shi Y, Lu W, Sun X, Feng X, Yan M, Cheng S, Wen T. Zhang X, et al. Signal Transduct Target Ther. 2026 Jan 22;11(1):37. doi: 10.1038/s41392-025-02498-z. Signal Transduct Target Ther. 2026. PMID: 41565617 Free PMC article. Clinical Trial.
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.
Ngoi NYL, Lee JY, Lim D, Thian YL, Lim YW, Chan JJ, Chay WY, Zhang Z, Gopinathan A, Lim SE, Low J, Ng J, Tong P, Lee YJ, Park J, Kim JW, Tan TZ, Zhu J, Tai BC, Choi CH, Kim BG, Tan DSP. Ngoi NYL, et al. Lancet Oncol. 2026 Feb;27(2):201-211. doi: 10.1016/S1470-2045(25)00662-X. Epub 2026 Jan 15. Lancet Oncol. 2026. PMID: 41548565 Clinical Trial.
50,718 results
You have reached the last available page of results. Please see the User Guide for more information.